TrialThe lancet. HIV2021

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

John Frater et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.